333 related articles for article (PubMed ID: 19519447)
41. Interleukin-6/soluble interleukin-6 receptor signaling attenuates proliferation and invasion, and induces morphological changes of a newly established pleomorphic malignant fibrous histiocytoma cell line.
Nakanishi H; Yoshioka K; Joyama S; Araki N; Myoui A; Ishiguro S; Ueda T; Yoshikawa H; Itoh K
Am J Pathol; 2004 Aug; 165(2):471-80. PubMed ID: 15277221
[TBL] [Abstract][Full Text] [Related]
42. Therapeutic targeting of IL-6 trans-signaling.
Rose-John S
Cytokine; 2021 Aug; 144():155577. PubMed ID: 34022535
[TBL] [Abstract][Full Text] [Related]
43. Sonic hedgehog inhibitors prevent colitis-associated cancer via orchestrated mechanisms of IL-6/gp130 inhibition, 15-PGDH induction, Bcl-2 abrogation, and tumorsphere inhibition.
Kangwan N; Kim YJ; Han YM; Jeong M; Park JM; Go EJ; Hahm KB
Oncotarget; 2016 Feb; 7(7):7667-82. PubMed ID: 26716648
[TBL] [Abstract][Full Text] [Related]
44. The classic signalling and trans-signalling of interleukin-6 are both injurious in podocyte under high glucose exposure.
Lei CT; Su H; Ye C; Tang H; Gao P; Wan C; He FF; Wang YM; Zhang C
J Cell Mol Med; 2018 Jan; 22(1):251-260. PubMed ID: 28881473
[TBL] [Abstract][Full Text] [Related]
45. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer.
Neurath MF; Finotto S
Cytokine Growth Factor Rev; 2011 Apr; 22(2):83-9. PubMed ID: 21377916
[TBL] [Abstract][Full Text] [Related]
46. The soluble form of the IL-6 receptor (sIL-6R alpha) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R alpha-induced AIDS-KS cell growth.
Murakami-Mori K; Taga T; Kishimoto T; Nakamura S
Int Immunol; 1996 Apr; 8(4):595-602. PubMed ID: 8722639
[TBL] [Abstract][Full Text] [Related]
47. Prevention of colitis-associated cancer: natural compounds that target the IL-6 soluble receptor.
Moriasi C; Subramaniam D; Awasthi S; Ramalingam S; Anant S
Anticancer Agents Med Chem; 2012 Dec; 12(10):1221-38. PubMed ID: 22583410
[TBL] [Abstract][Full Text] [Related]
48. Modulation of Pro-Inflammatory IL-6 Trans-Signaling Axis by Splice Switching Oligonucleotides as a Therapeutic Modality in Inflammation.
Gupta D; Orehek S; Turunen J; O'Donovan L; Gait MJ; El-Andaloussi S; Wood MJA
Cells; 2023 Sep; 12(18):. PubMed ID: 37759507
[TBL] [Abstract][Full Text] [Related]
49. IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3.
Greenhill CJ; Rose-John S; Lissilaa R; Ferlin W; Ernst M; Hertzog PJ; Mansell A; Jenkins BJ
J Immunol; 2011 Jan; 186(2):1199-208. PubMed ID: 21148800
[TBL] [Abstract][Full Text] [Related]
50. IL-6 signaling in diabetic nephropathy: From pathophysiology to therapeutic perspectives.
Feigerlová E; Battaglia-Hsu SF
Cytokine Growth Factor Rev; 2017 Oct; 37():57-65. PubMed ID: 28363692
[TBL] [Abstract][Full Text] [Related]
51. Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor α to gp130 expression: fusing experimental insights and dynamic modelling.
Reeh H; Rudolph N; Billing U; Christen H; Streif S; Bullinger E; Schliemann-Bullinger M; Findeisen R; Schaper F; Huber HJ; Dittrich A
Cell Commun Signal; 2019 May; 17(1):46. PubMed ID: 31101051
[TBL] [Abstract][Full Text] [Related]
52. Proteolytic control of Interleukin-11 and Interleukin-6 biology.
Lokau J; Agthe M; Flynn CM; Garbers C
Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt B):2105-2117. PubMed ID: 28630024
[TBL] [Abstract][Full Text] [Related]
53. Activation of an IL-6:STAT3-dependent transcriptome in pediatric-onset inflammatory bowel disease.
Carey R; Jurickova I; Ballard E; Bonkowski E; Han X; Xu H; Denson LA
Inflamm Bowel Dis; 2008 Apr; 14(4):446-57. PubMed ID: 18069684
[TBL] [Abstract][Full Text] [Related]
54. Viral Interleukin-6: Structure, pathophysiology and strategies of neutralization.
Suthaus J; Adam N; Grötzinger J; Scheller J; Rose-John S
Eur J Cell Biol; 2011; 90(6-7):495-504. PubMed ID: 21176991
[TBL] [Abstract][Full Text] [Related]
55. Novel path to IL-6 trans-signaling through thrombin-induced soluble IL-6 receptor release by platelets.
Marino M; Scuderi F; Ponte E; Maiuri MT; De Cristofaro R; Provenzano C; Rose-John S; Cittadini A; Bartoccioni E
J Biol Regul Homeost Agents; 2013; 27(3):841-52. PubMed ID: 24152848
[TBL] [Abstract][Full Text] [Related]
56. Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer.
Heo TH; Wahler J; Suh N
Oncotarget; 2016 Mar; 7(13):15460-73. PubMed ID: 26840088
[TBL] [Abstract][Full Text] [Related]
57. Local and systemic effects of interleukin-6 (IL-6) in inflammation and cancer.
Rose-John S
FEBS Lett; 2022 Mar; 596(5):557-566. PubMed ID: 34738234
[TBL] [Abstract][Full Text] [Related]
58. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
59. Interleukin-6 biology is coordinated by membrane bound and soluble receptors.
Rose-John S
Acta Biochim Pol; 2003; 50(3):603-11. PubMed ID: 14515143
[TBL] [Abstract][Full Text] [Related]
60. Molecular characterization of grass carp interleukin-6 receptor and the agonistic activity of its soluble form in head kidney leucocytes.
Wang X; Guo Y; Wen C; Lv M; Gan N; Zhou H; Zhang A; Yang K
Fish Shellfish Immunol; 2019 Mar; 86():1072-1080. PubMed ID: 30576778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
